New structural view of TB enzyme reveals route to irreversible inhibition

Tuberculosis remains a major global health threat: Mycobacterium tuberculosis (Mtb) is estimated to infect nearly a quarter of the world’s population, and the emergence of drug-resistant TB as well as HIV-TB co-infections has made new treatment strategies a pressing need. To look for fresh ways to attack the bacterium, Somnath Dutta and colleagues focused not on the usual drug targets but on metabolism. They studied a key enzyme called cystathionine β-synthase (MtbCBS), which is PLP-dependent and plays a central role in Mtb sulfur metabolism and redox regulation. Because this enzyme is essential for the bacterium’s metabolic balance, the team saw it as a promising therapeutic target. To understand how to stop it, the researchers determined the first high-resolution cryo-EM structure of MtbCBS bound to the inhibitor aminooxyacetic acid (AOAA). That structural picture formed the basis for further computational and biochemical work to explain how AOAA and similar compounds can lock the enzyme in an inactive state and provide a blueprint for designing new covalent inhibitors.

The study combined structural biology with computational chemistry and comparative biochemistry to reveal the molecular details of inhibition. Using cryo-EM, the team captured MtbCBS in complex with the inhibitor aminooxyacetic acid (AOAA) and then analyzed that structure with molecular dynamics (MD) simulations and quantum mechanics/molecular mechanics (QM/MM) calculations. These tools let them probe how atoms move and how chemical bonds and electronic features influence inhibitor binding. The cryo-EM structure highlighted two highly conserved active-site residues, T75 and Q147, that appear to be critical for stabilizing the inhibitor complex. In parallel, molecular mimic studies examined which precise structural factors and electronic properties of inhibitors were required for efficient and irreversible PLP-enzyme inhibition. Comparative inhibition studies confirmed the computational predictions, producing a consistent mechanistic picture of how AOAA and related molecules form stable, covalent interactions with the PLP-dependent active site.

Together, these findings provide the first mechanistic rationale for how PLP-dependent enzymes like MtbCBS can be irreversibly inhibited and offer a roadmap for future drug design. By pinpointing conserved residues T75 and Q147 and identifying the structural and electronic features that make AOAA an effective inhibitor, the work gives medicinal chemists concrete targets and principles to guide the development of covalent inhibitors. Although the study is focused on MtbCBS and tuberculosis, the authors highlight that the framework is generalizable: the same approach could be applied to other PLP-dependent enzymes that play roles in infectious diseases, cancer, and neurological disorders. The combination of cryo-EM, MD, QM/MM, and comparative inhibition experiments creates a multidisciplinary template that can accelerate the translation of structural insights into molecules with improved specificity and potency against PLP-dependent targets.